PLSM Pulsenmore Ltd. IFRS Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2064764 · Reporting currency ILS · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: ILS | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | 40.02M | 9.66M | 6.19M |
| Cost of revenue | 6.34M | 6.08M | 3.99M |
| Gross profit | 33.68M | 3.58M | 2.20M |
| R&D expense | 17.35M | 20.13M | 31.40M |
| SG&A expense | 16.68M | 15.34M | 16.95M |
| Interest expense | 7.22M | 540,000 | 16.21M |
| Pretax income | -15.85M | -36.79M | -58.44M |
| Income tax | 1,000 | -56,000 | 127,000 |
| Net income | -15.85M | -36.74M | -58.57M |
| EPS (basic) | 2.46 | 5.76 | 9.12 |
| EPS (diluted) | 2.46 | 5.76 | 9.12 |
| Balance sheet | |||
| Cash & equivalents | 21.60M | 41.17M | 23.87M |
| Receivables | 4.14M | 3.91M | — |
| Inventory | 19.93M | 23.09M | — |
| Current assets | 81.40M | 132.40M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 5.82M | 7.64M | 8.98M |
| Total assets | 101.85M | 141.83M | — |
| Current liabilities | 10.33M | 14.26M | — |
| Total liabilities | 18.76M | 44.94M | — |
| Shareholders' equity | 83.09M | 96.89M | 132.23M |
| Cash flow statement | |||
| Operating cash flow | -32.88M | -41.46M | -49.66M |
| Capital expenditure | 135,000 | 509,000 | 3.93M |
| Free cash flow | -33.01M | -41.97M | -53.59M |
| Investing cash flow | 13.85M | 58.58M | 56.71M |
| Financing cash flow | 4,000 | -1.56M | -1.14M |
| Depreciation & amortization | 2.80M | 2.85M | 2.40M |
| Stock-based compensation | 667,000 | 1.39M | 3.28M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, ILS, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.